

Journal section: *Oral Medicine and Pathology*
Publication Types: *Case Report*

doi:10.4317/jced.58323
<https://doi.org/10.4317/jced.58323>

Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report

Luis Monteiro ^{1,2,3}, Catarina Vasconcelos ¹, José-Júlio Pacheco ^{1,3}, Filomena Salazar ^{1,3}

¹ Oral Medicine and Oral Surgery Department, University Institute of Health Sciences (IUCS), Gandra 4585-116, Portugal

² Cancer Research Group, CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (IINFACTS), University Institute of Health Sciences (IUCS), Gandra 4585-116, Portugal

³ Oral Diseases Research Group, CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde (IINFACTS), University Institute of Health Sciences (IUCS), Gandra 4585-116, Portugal

Correspondence:

Rua Central de Gandra
1317, 4585-116 Gandra PRD, Portugal
luis.monteiro@iucs.cespu.pt

Received: 16/02/2021
Accepted: 26/03/2021

Monteiro L, Vasconcelos C, Pacheco JJ, Salazar F. Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report. J Clin Exp Dent. 2021;13(6):e626-9.

Article Number: 58323 <http://www.medicinaoral.com/odo/indice.htm>
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail: jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System

Abstract

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction often presenting as a post-surgery complication that may interfere in the quality of the patient's life. In the last decade, additionally to bisphosphonates, other drugs have been associated with MRONJ including other antiresorptive, antiangiogenic or multitarget drugs such as levatinib. The data on MRONJ associated to lenvatinib is scarce with no guidelines for best management option. Our aim is to report a case of MRONJ associated with lenvatinib and the useful of a non-invasive management using local photobiomodulation (PBM) therapy with a 635nm diode laser. **Material and Methods:** A 61-year-old female patient with a follicular thyroid carcinoma (stage IV) and taking lenvatinib presented to our Oral Medicine Unit with a painful non-healing ulcer with bone exposure, in the posterior right maxilla, after an extraction of a molar tooth which occurred 4 months previously. Bone rarefaction was detected in CT scan in the same affected area. We diagnosis a lenvatinib-related osteonecrosis of the Jaw (LRONJ). We performed 5 sessions of PBM treatment using a 635 nm diode laser, delivering 10J/ cm² in affected area. **Results:** At the end of the first session, a relief in the pain was already refereed by the patient. One month after, the oral mucosa was completely healed and tissue integrity was confirmed clinically and on panoramic radiograph and the patient referred an increase in her quality of life. On the last follow up after 6 months the patient was without any recurrence.

Conclusions: A lenvatinib-related osteonecrosis of the maxilla in a female patient is reported here for the first time. Moreover, a non-invasive management using PBM laser therapy has shown a successful healing of involved tissues and immediate symptoms relief improving the quality of life of the patient.

Key words: *Lenvatinib, MRONJ, osteonecrosis of the jaw, tyrosine kinase inhibitors, photobiomodulation.*

Introduction

Medication-related osteonecrosis of the jaw (MRONJ) is now a well-known adverse drug reaction that affect the maxillary bones and can infer seriously in the patient's quality of life (1,2). MRONJ has been defined by the American Association of Oral and Maxillofacial Surgery (AAOMS) as exposed bone or bone that can be detected through a extraoral or intraoral fistula, in the maxillofacial area, can persist for 8 or more weeks, occurring in patients which are or were in treatment with anti-angiogenic or antiresorptive drugs and in the absence of a previous radiation treatment or metastatic disease to the jaws (1). Osteonecrosis of the jaws (ONJ) can affect both jaws but typically affects the mandible. Clinically the lesion may cause swelling, discomfort, pain, infection, or even pathologic fracture (1,3-5).

The biopathology of MRONJ is not fully understood, however often reported as related with a knockdown of bone remodelling and impaired angiogenesis (1,6). The existence of local risk factors that contribute or triggers MRONJ are reported with invasive dental procedures as the main cause (including tooth extraction as the precipitating event in more than 50% of the cases) (1).

Since the primary association with bisphosphonates on the first cases other drugs have been related with an increased risk of inducing osteonecrosis of the jaw's including other antiresorptive drugs such as denosumab, tumour necrosis factor-alpha (TNF-) inhibitors (e.g. etanercept, adalimumab, infliximab), mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus), antiangiogenic drugs (e.g., bevacizumab) or other receptor tyrosine kinase inhibitors (RTKI) (e.g. sunitib, imatinib) sometimes directed to multiple targets such as lenvatinib (3,7-9). The association of lenvatinib with MRONJ is scarce on literature, providing no information on prevalence, clinical presentation or prognosis of potential MRONJ (9). Moreover, there is no data on management of lenvatinib-related osteonecrosis of the jaw's (LRONJ), as for example using conservative approach (e.g. laser photobiomodulation) or even invasive treatments. Using the CARE list guidelines for reporting case reports, the aim of this work is to report a case of a maxillary osteonecrosis associated with lenvatinib and the useful of a non-invasive management with photobiomodulation (PBM) therapy with a 635nm diode laser.

Case Report

A 61-year-old female patient was referred to our Oral Medicine Unit at the CESPU Parcerias Clinic, send by the GDP colleagues because of a painful non-healing socket in the maxilla after an extraction of a carious tooth. During the anamnesis, the patient referred that she felt an increasing amount of oral discomfort, drainage of fluids, and facial right side pain after the dental extraction of the posterior molar of right maxilla four months befo-

re. An intense pain on right and upper side of the mouth was described by the patient in the last weeks (VAS scale – 8). Her medical antecedents included a follicular thyroid carcinoma in stage IV stage with bony metastases (not in the craniofacial area) and submitted to total thyroidectomy, two years before. Antineoplastic therapy included lenvatinib 24mg orally once a month. She had performed palliative radiotherapy (not including jaws) for bone metastases. She did not take bisphosphonates or denosumab and reported no other important medications or allergies to any medication. On the contact with the GDP, a conservative approach was followed using local antiseptic agents (chlorhexidine rinses 0.2%, three times daily) and systemic antibiotic therapy (amoxicillin plus clavulanic acid, 875+125mg, two times daily) since the non-healing and bone exposure detection, although without any improvement in pain and healing. During the clinical examination, we observed a bone exposure in the posterior right maxilla with a 1.5cm of biggest size (Fig. 1A), with intense pain to palpation of adjacent




Fig. 1: Clinical presentation of a non-healing ulcer with bone exposure compatible with a lenvatinib-related osteonecrosis of the maxilla (A); CT scan showing bone rarefaction of maxillary posterior and right alveolar process (B and C).

tissues. We performed computed tomography (CT) scan that showed a bone density loss in the right and posterior area of the maxilla compatible with an area of osteonecrosis (Fig. 1B,C). Additionally, we observed also an almost full-filling of the right maxillary sinus. No associated neck lymphadenopathy was detected. Neoplastic disease was appropriately ruled out at this location. In the view of these observations we performed a diagno-

sis of a medication-related osteonecrosis of the maxilla associated with lenvatinib, grade III according to the AAOMS, 2014 (1), with a questionable prognosis.

After informed consent we performed a PBM treatment of the affected area using a 635 nm wavelength diode laser (Lasotronix®, Diode Laser DiodeLX model SMART M, Żytnia, Piaseczno, Poland). We performed 5 sessions during 5 consecutive weeks (one session per week) using an 8-mm cylindrical applicator handpiece, in a continuous mode for 25 seconds, delivering 10 J/cm² in affected area (Fig. 2). All safety measures for



Fig. 2: Application of handpiece for photobiomodulation at the affected area of LRONJ.

protecting the patient, operator, and assistant were followed. After the first session the patient reported an immediate relief in the treated area (VAS scale – 1). At the end of last session (~1 month after the beginning of treatment) the oral mucosa was completely healed and bone integrity was confirmed on panoramic radiograph. The patient referred any symptom since performing the laser sessions (including pain that corresponded to 0 in

VAS scale since the 2nd week of treatment) referring also an increase in her quality of life. On the last follow up the patient was without recurrence after 6 months of follow-up (Fig. 3).

Discussion

In the last decade, a wide spectrum of drugs has been described as related with osteonecrosis of the jaws which has led to the actual designation of MRONJ. However, few cases of osteonecrosis related with the family of RTKIs are reported and there are exceedingly rare cases of osteonecrosis associated with lenvatinib (3,9). We report here a conservative management of a LRONJ using PBM laser therapy with successful healing of involved tissues and immediate symptoms relief in a female patient with an advanced and metastatic follicular thyroid carcinoma.

Lenvatinib is a novel multitarget drug from the family of RTKI, directed mainly to vascular endothelial growth factor receptors, but also fibroblast growth factor receptors (FGF), platelet-derived growth factor receptor-alpha (PDGF), RET and KIT proto-oncogenes, showing antiangiogenic properties and potent anti-tumour activity. It is often used in treatment of advanced thyroid cancer, renal cell carcinoma and hepatocellular carcinoma (10,11). Possible side effects of this drug includes hepatotoxicity, cardiac dysfunction, arterial thromboembolic events, renal failure and amongst others wound healing complications (10,11). In our case, we confirm a mucosal non-healing and exposure of bone with more than 3 months, with a bone rarefaction observed in the CT scan, and without reports of other medication that could be related with osteonecrosis (except for lenvatinib) or radiotherapy including maxillary area. This let us to diagnose an LRONJ. Mauceri *et al.* (9) reported a LRONJ in an Italian man with an Hurthle cell thyroid cancer also located in a maxilla bone, with a fistula, purulent exudation and chronic pain.




Fig. 3: Complete healing of mucosal alveolar mucosa (A) and bone integrity on panoramic radiograph (B) in a follow-up of 6 months after the end of the treatment sessions.

PBM has been suggested to be a promising modality of treatment for patients with MRONJ in a single treatment or as an adjunct treatment with some studies reporting the beneficial effect of this method for these patients (4,12,13) including improve healing activity and reduce of pain as we observed in our patient. This has been reported in ONB patients also by the group of Romeo *et al.* (12). Moreover, during the initial period of four months only performing antibiotic therapy, any improvement of the lesion and symptomatology was seen. Interestingly, additionally to the reduction of pain already referred at the first sessions of PBM, at the end of the last session the mucosae were completely closed, which suggests the contribution of PBM for healing process, perhaps as a “gamechanger” in these lesions. No complications or side effects were observed. Also there was no need of invasive methods which is a real advantage for these patients many times with advanced disease status. PBM can influence many important biological processes including the activation of several cellular cascade events such as production of mitochondrial adenosine triphosphate and intracellular Ca⁺⁺, with consequent improve of cell energy metabolism, an increase in blood supply with potential improve on healing of the tissues. PBM has shown also to have analgesic and anti-inflammatory properties, increasing the release of beta-endorphins and reducing the amount of inflammatory cytokines including bradykinin, and prostaglandins which leads to a decrease inflammation, oedema and pain as also decontamination properties (14). This case reinforces also the importance of knowledge and awareness of the risk factors for osteonecrosis of the patients that presents to our clinics for oral treatments including local factors such as surgical procedures as also systemic factors and drug related factors specially for less common drugs related to MRONJ such as lenvatinib. (15). We acknowledge some limitations on this report, as naturally the power limitation of a single case report. However, to our knowledge, this is the first report of a LRONJ in a female patient with a successful conservative management using PBM laser therapy and without any secondary effects. Although we recognise that we could not prove with a single case report that the observed healing was due only to PBM treatment, we could clearly observe an elimination of pain after the laser treatment and improve the quality of life of the patient in this LRONJ.

In conclusion, we report a case of an lenvatinib-related osteonecrosis in a maxilla of a female patient with a metastatic follicular thyroid carcinoma, contributing for the worldwide awareness and knowledge of the potential effects of multitarget drugs from the RTKI family, in special lenvatinib, as risk factors of a MRONJ. Moreover, we show the usefulness of a non-invasive management using PBM laser therapy with successful healing of involved tissues and immediate symptoms relief improving the quality of life of the patient.

References

1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg.* 2014;72:1938-56.
2. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. *J Clin Oncol.* 2019;37:2270-90.
3. Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. *Med Oral Patol Oral Cir Bucal.* 2020;25:e71-e83.
4. Vescovi P, Giovannacci I, Merigo E, Meleti M, Manfredi M, Fornaini C, et al. Tooth extractions in high-risk patients under bisphosphonate therapy and previously affected with osteonecrosis of the jaws: surgical protocol supported by low-level laser therapy. *J Craniofac Surg.* 2015;26:696-9.
5. Fusco V, Cabras M, Erovigni F, Dell'Acqua A, Arduino PG, Pentenero M, et al. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. *Med Oral Patol Oral Cir Bucal.* 2020;24:318.
6. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches. *Stem Cells Int.* 2016;2016:8768162.
7. Bagan J, Peydró A, Calvo J, Leopoldo M, Jiménez Y, Bagan L. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. *Oral Dis.* 2016;22:324-9.
8. Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, Sounni NE. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. *Cancers (Basel).* 2020;12:731.
9. Mauerer R, Panzarella V, Morreale I, Campisi G. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. *Int J Oral Maxillofac Surg.* 2019;48:1530-2.
10. Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, et al. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. *Recent Pat Anticancer Drug Discov.* 2018;13:201-8.
11. Reed N, Glen H, Gerrard G, Good J, Lei M, Lyon AR, et al. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer. *Clin Oncol (R Coll Radiol).* 2020;32:e145-e53.
12. Romeo U, Galanakis A, Marias C, Vecchio AD, Tenore G, Palaia G, et al. Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results. *Photomed Laser Surg.* 2011;29:447-52.
13. Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. *Photomed Laser Surg.* 2008;26:37-46.
14. Monteiro L, Ferreira R, Resende T, Pacheco JJ, Salazar F. Effectiveness of Photobiomodulation in Temporomandibular Disorder-Related Pain Using a 635 nm Diode Laser: A Randomized, Blinded, and Placebo-Controlled Clinical Trial. *Photobiomodul Photomed Laser Surg.* 2020;38:280-8.
15. Patil V, Acharya S, Vineetha R, Nikhil K. Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study. *Oral Health Prev Dent.* 2020;18:505-9.

Funding

None.

Conflict of interest

There are no potential conflicts of interest.